Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma

This is a multi-institution, open label, phase I/II study of Iberdomide, Carfilzomib, and dexamethasone (KID) in patients with newly diagnosed transplant eligible MM.

Trial Details

NCT ID

NCT05199311

Phase

PHASE1 / PHASE2

Sponsor

Hackensack Meridian Health

Status

RECRUITING

Cancer Type

Newly Diagnosed Multiple Myeloma

Interventions

Carfilzomib
Iberdomide
Oral Dexamethasone

Locations (sample)

Washington D.C., District of Columbia, United States|38.89511,-77.03637
Hackensack, New Jersey, United States|40.88593,-74.04347

Key Eligibility Criteria

Documented newly diagnosed multiple myeloma
a. At least 25% of patients accrued should be high risk as defined by IMWG or mSMART criteria.
Patient should be deemed transplant eligible.
Patients may not have had more than 1 cycle of prior induction therapy. If a patient has had 1 cycle of prior multiple myeloma therapy, the patient…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Newly Diagnosed Multiple Myeloma Trials on Trialify →